Shanton Pharma Reports Encouraging Results in Their Phase 2b Gout Study, Paving the Way for Innovative Treatment Shanton Pharma has released promising data from their Phase 2b study of SAP-001, targeting refractory gout patients. This novel treatment shows breakthrough efficacy.

Shanton Pharma Reports Encouraging Results in Their Phase 2b Gout Study, Paving the Way for Innovative Treatment #USA #Princeton #Gout_Treatment #Shanton #SAP-001